Startups targeting fertility, PTSD and fungal skin infections are all in the frame for funding as Illumina Accleerator launches its seventh batch.

The first series A tranche will help commercialise a remedy for metabolic disorders and inflammatory conditions resulting from cardio-metabolic problems.

Cambridge spinout Crescendo Biologics has secured $70m in an IP Group and EMBL Ventures-backed round.

SoftBank made its second investment in the genomics tool developer as part of a round that enhanced its total funding to $185m.

Existing investors Edwards Lifesciences and Johnson & Johnson contributed to a round that took the medical device developer's total funding to almost $105m.

The Johnson & Johnson-backed cardiac medical device developer has completed a series B round that will fund clinical tests for its technology.

Astellas-backed immuno-oncology drug developer Crescendo Biologics has secured $70m in a Takeda Ventures-backed round.

The accelerator will connect AbbVie scientists with the lab of Kyriacos Nicolaou, pioneer of an approach for replicating natural molecules with cancer-fighting qualities.

The UCL spinout has secured an additional licence to a protein that aims to reduce side effects associated with its Car T immuno-oncological approach.

Iluminos will commercialise compounds with the potential to combat neurodegenerative diseases such as Alzheimer's.